ResearchDx is a Contract Diagnostics Organization (CDO) for the biopharmaceutical and diagnostic industries. The company provides comprehensive, integrated, flexible services for the in vitro diagnostic development process. From initial assay conceptualization, discovery, optimization and validation in a CAP/CLIA laboratory environment, through a complete set of clinical research services and on to regulatory approval, ResearchDx offers the services and solutions to meet complex diagnostics development needs. ResearchDx's primary service areas include assay research and development, clinical laboratory services, clinical research, diagnostic manufacturing, and consulting. Additional information is available at www.researchdx.com. ResearchDx will be exhibiting at DIA 2011 in Chicago, IL, June 19 – 22, booth #1238 and Chairing the session "Pharma-Diagnostics Relationship" at the Next Generation DX Summit in Washington D.C., August 23 – 25, 2011.
CompanDX is a molecular diagnostics company focused on biomarker discovery that uses its unique "Distiller" platform to derive small composite biomarker panels defining patient populations of significant unmet need. Working with Pharma and biotech companies CompanDX offers the opportunity to deliver stratified clinical trials utilizing companion diagnostic tests based on biomarkers derived from the "Distiller" bioinformatics platform. Privately-held, CompanDX is based in Nottingham, UK. Investors in the company include Lachesis and Mobius Funds. Additional information is available at www.compandx.com
Philip D. Cotter, PhD, FACMG, FFSc (RCPA)
Suite 147, 13766 Alton Parkway
Irvine, CA 92618
866-225-9195 / 510-332-0477
Copyright©2010 PR Newswire.
All rights reserved